COVID-19 Vaccine-Induced Lichenoid Eruptions-Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the Literature.

Lichen planus is a distinctive mucocutaneous disease with well-established clinical and histopathologic criteria. Lichenoid eruptions closely resemble lichen planus and may sometimes be indistinguishable from it. Systemic agents previously associated have included medications, viral infections and vaccines. Sporadic case reports of lichen planus and lichenoid reactions associated with COVID-19 vaccines have recently emerged. Herein, we review the world literature (31 patients) and expand it with a case series of 15 patients who presented with vaccine-induced lichenoid eruption (V-ILE). The spectrum of clinical and histopathologic findings is discussed with emphasis on the subset whose lesions manifested in embryologic fusion lines termed lines of Blaschko. This rare Blaschkoid distribution appeared in seven of the 46 patients studied. Of interest, all seven were linked to the mRNA COVID-19 vaccines. We believe that all lichenoid eruptions should be approached with a heightened index of suspicion and patients should be specifically questioned with regards to their vaccination history. When diagnosed early in its course, V-ILE is easily treated and resolves quickly in almost all patients with or without hyperpigmentation. Additional investigative studies regarding its immunopathology and inflammatory signaling pathways may offer insight into other Th1-driven autoimmune phenomena related to COVID-19 vaccination.

A case of Blaschkoid pityriasis rosea following COVID-19 vaccination: A rare exceptional occurrence

The launch of COVID-19 vaccines in India has raised the expectations of the dreadful COVID-19 pandemic ending in the future. Various mild and benign cutaneous manifestations of the different forms of the COVID-19 vaccine have been documented. Herein, we are reporting a unique case of Blaschkoid pityriasis rosea (PR) developing after COVID-19 vaccination. A forty-two-year-old female presented with PR along a linear arbitrary zone on the back at the level of L1-L2 extending to involve the abdomen and an oblique zone on the thigh. She was vaccinated with the first dose of the COVISHIELD ChAdOx1/nCoV-19 (recombinant) coronavirus vaccine six days before the onset of the lesions. There are only several case reports of typical pityriasis rosea occurring after COVID-19 vaccination. Our unique case depicts the occurrence of atypical PR after COVID-19 vaccination. [ FROM AUTHOR] Copyright of Our Dermatology Online / Nasza Dermatologia Online is the property of Our Dermatology Online and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)